| Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference | 05/30 07:30 | globenewswire.com |
| Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? | 05/24 08:27 | investorplace.com |
| Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 | 05/23 17:10 | globenewswire.com |
| EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member | 05/10 11:45 | businesswire.com |
| Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | 05/09 07:30 | globenewswire.com |
| Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting | 04/24 16:05 | globenewswire.com |
| Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference | 04/09 07:30 | globenewswire.com |
| Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment | 04/04 16:05 | globenewswire.com |
| Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium | 03/22 07:30 | globenewswire.com |
| Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences | 03/06 07:30 | globenewswire.com |